Merck KGaA To Build Biopharmaceutical Plant in Germany
Merck KGaA (Darmstadt, Germany) plans to invest 190 million euros ($245 million) to build a biopharmaceutical plant in Darmstadt, Germany. Production is expected to begin in 2010.
Darmstadt, Germany (Aug. 29)-Merck KGaA (www.merck.de) plans to invest 190 million euros ($245 million) to build a biopharmaceutical plant in Darmstadt, Germany. Production is expected to begin in 2010.
The new plant will mainly produce the monoclonal antibody "Erbitux" (cetuximab). Erbitux is currently manufactured for Merck KGaA by Boehringer Ingelheim (Ingelheim, Germany,
www.boehringer-ingelheim.com
) and ImClone Systems, Inc. (New York, NY,
www.imclone.com
). Merck KGaA acquired the rights to develop and market Erbitux outside the United States and Canada from ImClone Systems and shares marketing rights for Erbiutx with ImClone. Bristol-Myers Squibb Company (New York, NY,
www.bms.com
) and ImClone have rights for the product in the United States and Canada.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
